Kornimate/medical-research-clean huggingface dataset:
efficacy of pulmozyme® on arterial recanalization in post-thrombectomy patients managed for ischemic stroke (nets-target)

Conditions: Ischemic Stroke

Summary: the functional prognosis of patients with ischaemic stroke treated by thrombolysis and thrombectomy is associated with complete reperfusion of the occluded artery defined by an mtici 2c or 3 score at the end of thrombectomy. however, this complete reperfusion is only obtained in 60% of patients. most often, incomplete reperfusion is due to the persistence of distal occlusions, which are inaccessible to mechanical thrombectomy. drug treatment, combined with thrombectomy to increase the rate of complete reperfusion, would be a major advance in the management of these patients. this is a non-randomized, monocentric, open-label, phase ii trial to evaluate efficacy of dornase alfa intravenous administration in patients treated with intravenous thrombolysis and eligible for thrombectomy for ischemic stroke of the anterior circulation.


Eligibility criteria:
inclusion criteria: * ischemic stroke by proximal intracranial occlusion (internal carotid artery, middle cerebral artery in its m1 or m2 segment) isolated from the anterior circulation eligible for cerebral thrombectomy. * transferred to the nri block for a cerebral thrombectomy. * treated by thrombolysis intravenous (aleplase or tenecteplase) as recommanded by european stroke organisation * with dwi-aspect score\>5 to mri exclusion criteria: * pregnant or breastfeeding woman * known allergy to dornase alfa or one of its excipients.
comparative bioavailability study of azithromycin 200mg/5ml suspension following a 600mg dose under fed conditions

Conditions: Infections

Summary: the purpose of this study is to demonstrate the bioequivalence of azithromycin 200mg/5ml oral suspension.


Eligibility criteria:
inclusion criteria: * no clinically significant findings on physical exam, medial history or laboratory tests on screening exclusion criteria: * positive test for hiv or hepatitis b and c * treatment for drug or alcohol abuse * any other important criteria in the protocol
a non-randomized, open-label, single center phase 4 study of the effect and safety of iluvien® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (laser, anti-vegf) with or without intravitreal corticosteroid therapy

Conditions: Chronic Diabetic Macular Edema

Summary: a phase 4 trial evaluating the effect and safety of iluvien in chronic dme patients insufficiently responsive to available therapies.


Eligibility criteria:
inclusion criteria: 1. patients ≥18 years of age, of either sex that have signed informed consent / been well informed by the treating physician. 2. dme based on investigator's clinical evaluation and demonstrated using fundoscopic photography and spectral domain oct. 3. mean central foveal thickness (central subfield thickness) ≥350 microns in the study eye as measured using spectral domain oct. 4. vision impairment (20/60 to 20/400 using snellen visual acuity equivalent) related to dme. 5. previous treatment in the study eye with laser photocoagulation for dme, including focal/grid and pan-retinal, at least 3 months prior to the screening visit and ≥3 monthly anti-vegf treatments (group 1). 6. previous treatment in the study eye with laser photocoagulation for dme at least 3 months prior to the screening visit (group 2) and treatment with an intraocular anti-vegf therapy not possible. 7. patients considered as insufficiently responsive to prior therapy for dme, as defined by the study physician. exclusion criteria: 1. iop \>21 mmhg at screening in the study eye. 2. historical rise in iop \>25 mmhg following treatment with an intravitreal corticosteroid in the study eye. 3. use of ≥2 iop-lowering medications to control iop at screening in the study eye. 4. patients that have vitreomacular traction in dme and opaque media in the study eye. 5. patients with severe proliferative diabetic retinopathy requiring pan retinal photocoagulation in the study eye. 6. pregnant or breastfeeding. 7. patients diagnosed with active angiographic central vein ischaemia prior to screening in the study eye. 8. patients that have received pan retinal photocoagulation or undergone cataract surgery in the 3 months prior to the study start date in the study eye. 9. patients with contraindications according to the current spc: 1. the presence of pre-existing glaucoma. 2. active or suspected ocular or periocular infection. 3. the patient is hypersensitive to the active agent or to one of the excipients.
effect of high frequency oscillatory highflow nasal cannula on desaturations and bradycardia in preterm infants

Conditions: Apnea of Prematurity; Infant, Premature, Diseases

Summary: this study evaluates the effect of non-invasive high frequency oscillations applied via a highflow nasal cannula ('osciflow') compared to highflow nasal cannula without oscillations (hf) on desaturations and bradycardia in premature infants. it uses a crossover design. infants are randomized to begin the study with either osciflow or hf. both modes are applied for 4 hours. infants are monitored with an oximetry sensor to measure peripheral oxygen saturation (spo2) and pulse rate, and with a transcutaneous co2-transducer. further measurements include respiratory rate and 'bernese pain scale' evaluated by nursing staff and electrical impedance tomography (eit) in a subset of patients.


Eligibility criteria:
inclusion criteria: * preterm infants born with a gestational age of \<35 weeks * \>72 hours old * on ncpap with peep 5 mbar and fio2 \<0.3 exclusion criteria: * severe congenital malformations adversely affecting life expectancy

Keywords: non-invasive respiratory support non-invasive high frequency oscillatory ventilation highflow nasal cannula
assessment of rituximab's immunomodulatory synovial effects (the arise study)

Conditions: Rheumatoid Arthritis

Summary: using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur as a result of treatment with rituximab.

using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur after treatment with rituximab.

Eligibility criteria:
inclusion criteria: * active rheumatoid arthritis * use of concomitant methotrexate exclusion criteria: * use of disease-modifying anti-rheumatic drugs (dmards)/biologics other than methotrexate * serious medical conditions that would preclude the use of the treating agent

Keywords: active disease despite concomitant methotrexate
colostral milk and blood il-6 levels in types of labour

Conditions: Indications for Care in Pregnancy; Labor; and Delivery

Summary: the comparison of serum and colostral melatonin, and il-6 levels between women with vaginal delivery, emergency cesarean section and elective cesarean section

in this prospective randomized study, the investigators aimed to show the changes in the melatonin levels in colostral milk in spontaneous vaginal delivery,emergency cesarean and elective cesarean section patients and changes in blood il-6 level before and after the delivery in same patient groups. the investigators randomized 30 cases for each group for comparisons.time range seems short in this study but participating hospital setting is a busy maternity hospital thus it will be performed easily. the purpose of this study is to demonstrate the beneficial effect of spontaneous vaginal delivery on the secretion of melatonin which is solely secreted by the mother and the newborn is dependent on maternal milk oriented melatonin until 12 th week after delivery

Eligibility criteria:
inclusion criteria * pregnant women reached term * patients with spontaneous vaginal delivery * patients preferred cesarean section electively * patient who had emergency cesarean section without additional medical or surgical problems exclusion criteria * women who had history of intrauterine fetal loss * hypertention during pregnancy * anemia * thyroid diseases * patients with chronic diseases * smokers * drug users

Keywords: melatonin,colostral milk,il-6, delivery, cesarean section
pediatric and adult cerebral arteriovenous malformation neurofunctional outcomes

Conditions: Cerebral Arteriovenous Malformation

Summary: cerebral arteriovenous malformations (avms) are abnormal tangles which are usually believed congenital. avm can cause different symptoms depending on where it is located, but the most common symptoms are intracranial hemorrhage and seizure. outcomes of avm patients can be very different due to factors like the location of lesion, age, sex etc. generally, more early the intervention was taken, the risk of adverse events would be lower. but the selection of surgical timing for pediatric avm patients is hard to judge, due to children's cerebral vessels angioarchitecture can be still developing with their age. some previous studies indicated that there is no difference in intervention outcomes between pediatric and adult avm patients, so pediatric patients should undergo more aggressive intervention. dopa study aims to compare the clinical intervention outcomes of both pediatric and adult patients with eloquent region cerebral arteriovenous malformations, helping to determine the treatment strategy.

follow-up: in the investigators' neurosurgical center, follow-up was conducted for all participants at the first 3-6 months and annually after discharge by clinical visit and telephone interview. study overview: dopa will aim on outcomes of both pediatric and adult avms patients who underwent intervention in investigators' institution. intervention strategies contains microsurgical resection, embolization, embolization + radiosurgery, and single-stage hybrid surgery (embolization + resection). outcomes will be measured by a neurologist using modified rankin scale (mrs). participants' mrs\<2 will be considered as a good outcome and investigators will keep follow-up with every patient for at least 3 years. sample size: about 300 patients will be enrolled in this study, and adults and children will account for half. all kinds of intervention will be included. the distribution of different strategies is excepted as: 30% resection, 20% embolization, 30% embolization + radiosurgery and 20% hybrid surgery. study endpoints: the patients' mrs, occlusion rate and complication will be evaluated at 2 weeks, discharge from hospital, 1 year and 3 years after the first-time intervention.

Eligibility criteria:
inclusion criteria: * the diagnosis of avm was confirmed with digital subtraction angiography (dsa) and/or magnetic resonance imaging(mri). * patients had underwent interventions in our institution. * avms were located in eloquent area. exclusion criteria: * patients with multiple avms. * patients with hereditary hemorrhagic telangiectasia (hht). * patients with missing clinical and imaging data.
the influence of having bariatric surgery on the pharmacokinetics, safety and efficacy of the novel non-nucleoside reverse transcriptase inhibitor doravirine

Conditions: HIV Infections; Bariatric Surgery Candidate

Summary: a multicentre phase iv study to collect evidence that a doravirine-based regimen can be safely and effectively administered to virologically suppressed hiv-infected patients undergoing bariatric suregery.


Eligibility criteria:
inclusion criteria: * hiv-infected * vl suppressed \<40c/ml for at least 6 months, blips are allowed * planned to have bariatric surgery (gastric bypass or gastric sleeve) * able to sign informed consent * age \> or equal to 18 years * using doravirine for at least 4 weeks prior to bs with vl \< 40 copies/ml prior to the surgery exclusion criteria: * history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation * requires or is anticipated to require any of the prohibited medications known to contradict/interact with doravirine * has significant hypersensitivity or other contraindication to doravirine * creatinine clearance \<40 ml/min * severe liver dysfunction (diagnosed liver cirrhosis: child-pugh c) * pregnancy or planning to be pregnant during first 6 months postbariatric surgery.

Keywords: doravirine pharmacokinetics
a study to assess the safety and efficacy of zpl389 in patients with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of zpl389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks

a screening period of up to 4 weeks was followed by a 16-week double blinded treatment period. after the end of treatment visit, subjects were offered the possibility of ongoing treatment in the extension study (czpl389a2203e1/ nct03948334), or of entering the 4 week treatment-free follow-up period.

Eligibility criteria:
inclusion criteria: * subjects must give a written, signed and dated informed consent * chronic atopic dermatitis present for at least 1 year before baseline * moderate to severe atopic dermatitis defined as per easi, iga and bsa. * documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable * candidate for systemic treatment exclusion criteria: * any skin disease that would confound the diagnosis or evaluation of atopic dermatitis disease activity * use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. * history of hypersensitivity to any of the study drug constituents or to drugs of similar chemical classes. * participation in prior zpl389 studies

Keywords: atopic dermatitis ad eczema atopic eczema itch, pruritus histamine 4 receptor antagonist h4r zpl389 zpl389a2203 dermatitis
a phase 3 safety and efficacy study of intravitreal administration of zimura (complement c5 inhibitor)

Conditions: Geographic Atrophy; Macular Degeneration

Summary: the objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (amd)

participants were randomized in a 1:1 ratio to the following monthly treatment groups: * avacincaptad pegol 2 mg * sham at month 12, the participants in the avacincaptad pegol 2mg treatment group were re-randomized to receive the study drug either on a monthly basis or on an every other month basis the participants initially randomized to sham treatment continued with monthly sham administration through month 23 all participants had a final follow up visit at month 24

Eligibility criteria:
inclusion criteria: * subjects of either gender aged ≥ 50 years * diagnosis of non-foveal ga secondary to dry amd exclusion criteria: * any prior treatment for amd (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals * any intraocular surgery or thermal laser within 3 months of trial entry. * any prior thermal laser in the macular region, regardless of indication * any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks. * previous therapeutic radiation in the region of the study eye * any sign of diabetic retinopathy in either eye

Keywords: geographic atrophy (ga) age-related macular degeneration amd complement c5 inhibitor avacincaptad pegol izervay
intensive management for gestational diabetes

Conditions: Gestational Diabetes

Summary: this is a randomized clinical pilot trial designed to assess the feasibility of randomizing obese women with gdm to lower glycemic thresholds compared to standard care. maternal and cord blood metabolic profiles, neonatal body composition, and maternal sleep quality and duration will also be compared between groups.

the investigators will randomize 60 obese pregnant women with a new diagnosis of gestational diabetes using the carpenter-coustan criteria in a 1:1 fashion to either standard care or intensive therapy. subjects will be randomized to either standard care or intensive therapy at the first study visit, which will occur between 12-32 weeks of gestation after they have completed their gestational diabetes testing. neither patients nor their providers will be blinded to patient study group. all women will receive standard nutritional counseling at the time of diagnosis, and they will also be treated with either glyburide or insulin as dictated by standard care. women will return for a second study visit between 32-36 weeks of gestation to assess the impact of their glycemic target groups on overall glycemic control. the investigators will also collect information on the type and dose of each medication required to maintain glycemic control in women randomized to either standard care or intensive therapy. in addition to standard glucose monitoring 4x/day (fasting and one-hour post breakfast, lunch, and dinner), the investigators will utilize blinded continuous glucose monitors (ipro, medtronic) at each study visit. because women with gdm are receiving active management of their blood sugars and dietary counseling, the investigators will assess cgm for 5 consecutive days both at study enrollment and again between 32-36 weeks. study participants will complete food diaries during their cgm monitoring to correlate food intake with glycemic variation. the investigators will also compare maternal and cord blood metabolic profiles, neonatal body composition, and maternal sleep quality and duration between groups.

Eligibility criteria:
inclusion criteria: * maternal age between 18-45 years * singleton birth * planned delivery at ou medical center * gdm diagnosed between 12-32 weeks' gestation by either a 50 gram * one hour gct \>200 mg/dl or two or more abnormal values on a 100 gram ogtt using the carpenter-coustan criteria * pre-pregnancy bmi ≥26 kg/m2. exclusion criteria: * maternal tobacco use * planned delivery prior to 34 weeks of gestation * significant fetal anomalies * chronic hypertension requiring medication * other vascular disease * known renal disease with a baseline serum creatinine \>1.5 mg/dl * maternal rheumatologic disorders requiring medication * maternal human immunodeficiency virus (hiv) or hepatitis * as the specimen storage facility is not accredited to handle such samples * steroid use within 7 days.
effect of omega 3 fatty acids on the vascular calcification biomarkers fetuin a and osteoprotegerin in patients with crf

Conditions: Chronic Renal Failure

Summary: study the effect of omega 3fatty acids on the vascular calcification biomarkers fetuin -a and osteoprotegerin (opg) in dialysis patients.

2-all participants agreed to take part in this clinical research and provide informed consent. 3-patients undergo both undergo hemodialysis (hd) will be enrolled from dialysis unit in al moussa hospital alexandria. 4-serum samples will be collected for measuring the biomarkers. 5-our design is randomized, controlled, open-intervention study. 6- all enrolled patients will be divided into 2 groups, group 1 will be 40 patients that will take omega 3fatty acids and group 2 will be 20 patients will not take omega 3 fatty acids. 7-all patients will be followed up during 6 months' period. 8-statsicial tests appropriate to the study design will be conducted to evaluate the significance of the results. 9-measuring outcome: the primary outcome is the increase of the serum levels of the vascular calcification biomarkers after 6months. 10-results, conclusions, discussion and recommendations will be given. inclusion criteria: * 60 hemodialysis patients, (20-80) years old. * enrolled hd patients received regular hd 3 times weekly (on chronic maintenance for at least 6months). exclusion criteria: people with active infections (fever or any evidence of infections), known malignancy, connective tissue disorders, immunosuppressive therapy, and inflammatory diseases, current use of warfarin ,history of fish oil/omega 3 allergies were excluded. methodology: * feutin-a and osteoprotegrin (opg) will be determined by elisa. * serum lipid levels, phosphorus, calcium, parathormone (i-pth), alkaline phosphatase, albumin and creatine levels. * bmi

Eligibility criteria:
inclusion criteria: * 60 hemodialysis patients, (20-80) years old. * enrolled hd patients received regular hd 3 times weekly (on chronic maintenance for at least 6 months). exclusion criteria: * people with active infections (fever or any evidence of infections), known malignancy, connective tissue disorders, immunosuppressive therapy, and inflammatory diseases, current use of warfarin ,history of fish oil/omega 3 allergies were excluded.
effects of imatinib mesylate in polycythemia vera

Conditions: Polycythemia Vera

Summary: the purpose of this study is to determine the activity of glivec 400 mg po daily, as single agent, in inducing a haematological response in polycythemia vera. the patients will be asked to have additional bone marrow and blood samples collected: these samples will be used to evaluate how the disease is responding to the drug.

hematocrit \<45% in men or \<42% in women at 1°evaluation within 6 months in case of complete or partial responsiveness, experimental treatment will be continued until 12 months in case of disease progression or treatment failure, experimental drug will be withdrawn and patient will be out of the study

Eligibility criteria:
inclusion criteria: * diagnosis of polycythemia vera requiring treatment with either phlebotomy or hydroxyurea * age \>18 years * signed written informed consent form exclusion criteria: * pregnancy or breast-feeding * creatinine \>3 max nv * bilirubin \>3 max nv * ast/alt \>3 max nv * concomitant and severe psychiatric disorder * concomitant neoplastic disease
impact of aortic annulus calcification on long-term outcomes following transcatheter aortic valve replacement: saint-tavr calcium registry

Conditions: Aortic Stenosis

Summary: the goal of this observational study is to learn about the long-term effects of aortic valve annular calcification in patients undergoing transcatheter aortic valve replacement (tavr). the main question it aims to answer is: does the degree of aortic valve annular calcification prior to tavr influence long-term clinical outcomes, including major adverse cardiovascular events including all-cause mortality, over a 3-year period? participants who have undergone tavr as part of their regular medical care for severe aortic stenosis will have their pre-procedural imaging and clinical outcomes evaluated for a 3-year follow-up period.


Eligibility criteria:
inclusion criteria: 1. adults aged 19 years or older. 2. patients who have undergone transcatheter aortic valve replacement (tavr) for severe aortic stenosis. 3. individuals who have voluntarily provided written informed consent to participate. exclusion criteria: 1. individuals who have not provided written informed consent for this study.
epidemiological profile of ophthalmological care in the public service in brazil

Conditions: Eye Abnormalities

Summary: epidemiological study about eye discomfort complaints, comorbidities and diagnosis at a brazil's ophthalmological public care service

1. 1670 individuals underwent an ophthalmologic evaluation 2. the data were obtained through the analysis of the medical records with the icd-10 registration 3. the studied variables were age and sex of patient, origin, eye discomfort complaints, comorbidities and diagnosis (icd-10). 4. the purpose was to evaluate epidemiological aspects of eye diseases in a public service

Eligibility criteria:
inclusion criteria: * patients assisted in public service exclusion criteria:

Keywords: prevalence vision disorders eye diseases visual acuity primary health care